AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018

Aug 10, 2018

SEC Form 4/A — Form 4/A

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-03-28

Reporting Person: Biller Scott (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-28	Stock option (right to buy)	$0.4675	M	37	Disposed	2020-12-06	Common stock (37)	Direct
2018-03-28	Stock option (right to buy)	$2.34	M	4100	Disposed	2022-04-05	Common stock (4100)	Direct

Footnotes

F1: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction.

F2: This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015.

F3: This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015.